Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Rojkjaer LisaOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:187,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Schorno Dean LOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:78,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Schorno Dean LOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:62,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Santos David AOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:78,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Santos David AOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Rodriguez Raul ROwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Rodriguez Raul ROwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Furey Raymond J.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:78,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Furey Raymond J.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:93,750Price:--
-
Feb 05, 2024 (filed on Feb 06, 2024)Insider Name:Santos David AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,918Price:$1.14
Filings by filing date
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Rojkjaer LisaOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:187,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Schorno Dean LOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:78,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Schorno Dean LOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:62,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Santos David AOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:78,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Santos David AOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Rodriguez Raul ROwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Rodriguez Raul ROwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Furey Raymond J.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:78,500Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Furey Raymond J.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:93,750Price:--
-
Feb 05, 2024 (filed on Feb 06, 2024)Insider Name:Santos David AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,918Price:$1.14
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.rigel.com |
IR: | See website |
Key People | ||
Raul R. Rodriguez President, Chief Executive Officer, Director | Dean L. Schorno Chief Financial Officer, Executive Vice President | Raymond J. Furey Executive Vice President, General Counsel, Company Secretary |
Lisa Rojkjaer Executive Vice President, Chief Medical Officer | David A. Santos Executive Vice President, Chief Commercial Officer |
Business Overview |
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. |
Financial Overview |
For the fiscal year ended 31 December 2023, Rigel Pharmaceuticals Inc revenues decreased 3% to $116.9M. Net loss decreased 57% to $25.1M. Revenues reflect Contract revenues from collaborations decrease of 71% to $11.5M, Government contract decrease of 76% to $1.1M. Lower net loss reflects Research and development - Balancing val decrease of 61% to $22.4M (expense), Stock-based Compensation in SGA decrease of 34% to $6.7M (expense). |
Employees: | 147 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $197.37M as of Dec 31, 2023 |
Annual revenue (TTM): | $116.88M as of Dec 31, 2023 |
EBITDA (TTM): | -$19.25M as of Dec 31, 2023 |
Net annual income (TTM): | -$25.09M as of Dec 31, 2023 |
Free cash flow (TTM): | -$20.74M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $2.67M as of Dec 31, 2023 |
Shares outstanding: | 175,404,663 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |